Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.75 EUR | -0.93% | -1.04% | -24.20% |
04-25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.20% | 813M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- Formycon's Interim Analysis of Late-stage Trial of Aflibercept Biosimilar Candidate Shows Efficacy Against Macular Degeneration